Courtney is a seasoned biopharmaceutical executive with 25 years of strategic and operational experience in innovative, fast-growing companies. She brings deep scientific expertise and strategic leadership to the field, specializing in Oncology and Rare Disease. Courtney has a proven track record of advancing small molecule programs, AAV gene therapies, and RNA-targeted therapies from discovery into clinical development. She is recognized for her clarity of vision, strong leadership, and business acumen, achieving significant success in building and leading high-performing teams that drive innovation and operational excellence.

Courtney served as Vice President of Program Management, Strategy and Operations at Decibel Therapeutics, leading the development of multiple gene therapy assets and alliance partnership with Regeneron resulting in the acquisition of all assets. Prior to that she served as Senior Director of Research and Development at Solid Biosciences, where she advanced gene therapy candidates on accelerated pathways.

With expertise spanning program management, regulatory strategy, risk assessment, and platform development, Courtney is passionate about bridging science to commercial value. As a dedicated leader in the biotechnology space, she is committed to transforming cutting-edge science into impactful therapies for patients in need.